Edition:
United Kingdom

AVROBIO Inc (AVRO.OQ)

AVRO.OQ on NASDAQ Stock Exchange Global Select Market

25.12USD
7 Dec 2018
Change (% chg)

$-2.14 (-7.85%)
Prev Close
$27.26
Open
$27.08
Day's High
$27.50
Day's Low
$24.45
Volume
29,495
Avg. Vol
33,345
52-wk High
$53.70
52-wk Low
$20.30

Summary

Name Age Since Current Position

Bruce Booth

Chairman of the Board

Geoff MacKay

President, Chief Executive Officer, Director

Chris Mason

Chief Science Officer

Deanna Petersen

Chief Business Officer

Kim Warren

Head of Operations

Phillip Donenberg

57 2018 Director

Biographies

Name Description

Bruce Booth

Dr. Bruce Booth Ph.D. is Chairman of the Board of the Company. Bruce Booth is a partner at Atlas Venture and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce is currently chairman of AvroBio, miRagen Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Quartet Medicine, and also serves on the boards of Lysosomal Therapeutics, Magenta Therapetics, Unum Therapeutics, and Zafgen (NASDAQ:ZFGN). He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB, Shire, Pfizer, and Takeda. He also serves on the board of the National Venture Capital Association. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes. He has published numerous scientific papers and has authored various biotech venture capital review articles, including several in Nature Biotechnology. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. His work focused on the study of HIV and tumor immune responses. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Geoff MacKay

Mr. Geoff MacKay is President, Chief Executive Officer and Director of the Company. Geoff is an experienced CEO with proven success leading innovative businesses. While CEO of Organogenesis Inc., the company treated 1 million patients with living cell therapies, received the first FDA CBER allogeneic cell-therapy approval and achieved an unparalleled position within regenerative medicine. Geoff was founding CEO of eGenesis, applying CRISPR Cas-9 gene editing to xenotransplantation. Geoff spent 11 years at Novartis in senior leadership positions within the Global Transplantation & Immunology franchise. Past activities include Chairman of the Board of MassBio, Chairman of the Board of the Alliance of Regenerative Medicine, and Advisory Council to the Health Policy Commission for Massachusetts. Through his public and private enterprise work, Geoff is dedicated to applying innovation to reshape and improve the quality of healthcare.

Chris Mason

Dr. Chris Mason is Chief Science Officer of the Company. Chris is a clinician-scientist with over 20 years of cell and gene therapy experience including Full Professor of Regenerative Medicine Bioprocessing at University College London. He has a multidisciplinary track record spanning R&D, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and commercialization. Chris is co-founder of the London Regenerative Medicine Network, trustee of the UK Stem Cell Foundation and on the UK-Israel Science Council. Current SAB appointments include; public and private companies, the UK Cell Therapy Catapult and the Canadian Centre for the Commercialization of Regenerative Medicine. Chris is Senior Editor of the journals ‘Cell and Gene Therapy Insights’ and ‘Regenerative Medicine’.

Deanna Petersen

Ms. Deanna Petersen is Chief Business Officer of the Company. Deanna is a broadly skilled senior executive with leadership experience in global business development and strategic planning. Deanna previously was the head of business development for Shire’s rare disease business where she and her team identified and evaluated new business opportunities, and negotiated and executed more than 40 transactions in 5 years (public and private M&A, licenses and other partnerships), including a $4.2 billion dollar acquisition of ViroPharma. Prior to joining Shire, Deanna was Vice President of Business Development at Agenus Inc. and at Coley Pharmaceutical Group. Deanna is on the Board of Directors for Tecogen, Inc. (TGEN) and was previously on Boards for Armagen, American DG Energy (ADGE), the Massachusetts Biotechnology Association, the Boston Chapter of the Healthcare Businesswomen’s Association and for the Boston BioPharma Executive Council.

Kim Warren

Dr. Kim Warren Ph.D. is Head of Operations of the Company. Kim is experienced scientist with entrepreneurial and business management experience in cell therapy. She spent the last 10 years at Lonza, developing a services business, including tissue acquisition, process development, bioassays and related services to support GMP manufacturing of cellular therapeutics. Kim also headed R&D at Cambrex, developing cell-based research products. She founded and ran Poietic Technologies, acquired by Cambrex in 1999. She has also held research positions in pharma (Otsuka) and biotech (Cetus). Kim has a Ph.D. in Comparative Physiology from University of Maryland and postdoctoral training in Immunology at USUHS, Bethesda MD.

Phillip Donenberg

Basic Compensation

Options Compensation